William Mack & Associates’s Xeris Biopharma Holdings XERS Stock Holding History

William Mack & Associates’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$52.8K	Buy	+5,524	New	+$46.7K	0.02%	237

Other funds holding XERS

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

William Mack & Associates's XERS Position: Q3 2026 in Review

William Mack & Associates opened a new position in Xeris Biopharma Holdings (XERS) in Q3 2026: 5,524 shares worth $52.8K. The stake represents 0.02% of the portfolio and ranks #237 among its holdings.

182 funds tracked by Wall St. Rank hold XERS as of Q3 2026.

William Mack & Associates held 5,524 shares of Xeris Biopharma Holdings worth $52.8K as of Q3 2026.
Xeris Biopharma Holdings was a new William Mack & Associates position in Q3 2026.
Xeris Biopharma Holdings made up 0.02% of William Mack & Associates's portfolio in Q3 2026, its #237 holding.
182 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2026.

Based on William Mack & Associates's 13F filing for Q3 2026, filed 27 Oct 2026.